Are Genus plc And Dechra Pharmaceuticals plc Better Buys Than GlaxoSmithKline plc?

Which of these 3 pharmaceutical companies should you add to your portfolio? Genus plc (LON: GNS), Dechra Pharmaceuticals plc (LON: DPH) or GlaxoSmithKline plc (LON: GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

While shares in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) have disappointed in the last year, it has not been the same story for a number of its pharmaceutical rivals. In fact, shares in Genus (LSE: GNS) and Dechra (LSE: DPH) have soared in the last 12 months by 35% and 55% respectively, which is a much healthier return than GlaxoSmithKline’s fall of 6%.

Does this mean, then, that Genus and Dechra are better buys that GlaxoSmithKline? Or, is their larger peer now better value for long term investors?

Margin Of Safety

Suffice to say, it is rare to find a pharmaceutical company that offers a wide margin of safety. That’s even more the case when comparing them to the wider market, since they tend to offer stronger growth in the long run, while their lack of strong correlation to the macroeconomic outlook marks them out as strong defensive plays. So, while all three companies trade at premiums to the FTSE 100, their margins of safety still differ somewhat.

For example, Genus and Dechra currently trade on price to earnings (P/E) ratios of 25.6 and 26.1 respectively, which are significantly higher than the FTSE 100’s P/E ratio of around 16. Certainly, both companies are set to increase their bottom lines at a much faster rate than the wider index, with growth of 16% in the current year and 12% next year pencilled in for Genus. Meanwhile, Dechra is expected to grow its profit by 8% this year and 11% in the following year.

The problem, though, is that these above average growth rates appear to be adequately priced in – especially after their aforementioned share price rises in the last year. As such, there is little margin of safety, which could mean that share price growth is not as impressive as the market is currently anticipating.

GlaxoSmithKline, of course, is lacking significant growth appeal over the next couple of years. In fact, its bottom line is forecast to fall by 4% this year before recovering by 3% next year. So, compared to Genus and Dechra, it is expected to post disappointing results. However, GlaxoSmithKline trades on a much lower rating than its two smaller peers, with it having a P/E ratio of just 16.8. This indicates that if the company is able to deliver on the efficiencies it has planned and which are set to catalyse its bottom line, its valuation has scope to move substantially upwards.

Total Return

Of course, with sales and earnings of pharmaceutical companies being relatively volatile, an income element to total return can be highly worthwhile for investors. In this space, GlaxoSmithKline is the clear winner of the three companies, since it has a dividend yield of 5.3% at the present time. This compares favourably to Genus and Dechra, which have yields of just 1.4% and 1.6% respectively.

And, looking ahead, the total return from GlaxoSmithKline could be higher than that of Genus or Dechra, since it offers a much cheaper share price. And, from next year, it is expected to return to growth, which could act as a catalyst on investor sentiment. So, while Genus and Dechra have massively outperformed GlaxoSmithKline in the last year, the tables could turn for investors taking a long term view.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

2 of the best stocks to buy now with £500

I think that Berkshire Hathaway and Activision Blizzard are two of the best shares to buy today. I think they…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

I bought 10 cheap shares. Here’s what happened next

After recent price falls, we bought 10 cheap shares for extra passive income in future. This mini-portfolio offers a tasty…

Read more »

Close up view of Electric Car charging and field background
Investing Articles

Is now a good time to buy Chinese EV stocks as economic growth slows?

Chinese EV stocks tend to trade at a considerable discount to their US counterparts. And that's one reason I like…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

I’d happily start investing in today’s stock market – here’s why

The stock market has been moving up even as the economy has been looking shakier. Would our writer start investing…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Up 22% in a month! This FTSE 100 takeover target could rise further

A takeover bid for an FTSE 100 firm is big news. Here's what I'm doing about RS Group shares after…

Read more »

Young female analyst working at her desk in the office
Investing Articles

Income shares could help me turn £300 into £500. Here’s how

Our writer believes investing in the right income shares over the long term could be lucrative. Here is his approach.

Read more »

Bearded man writing on notepad in front of computer
Investing Articles

I bought these FTSE 250 shares for fat dividends!

These two FTSE 250 shares have gained in value since I bought them recently. But I still see these stocks…

Read more »

Shot of a young Black woman doing some paperwork in a modern office
Investing Articles

Should I buy this REIT to add to the others that pay me juicy dividends?

Jabran Khan looks closer at this real estate investment trust (REIT) and decides if he would add the shares to…

Read more »